In November 2022 the International Tennis Integrity Agency (ITIA), on behalf of the International Tennis Federation (ITF), reported multiple anti-doping rule violations against the Polish tennis player Kamil Majchrzak.
In this case the presence had been established of the prohibited substances: LGD-4033 (Ligandrol), SARM S-22 (Ostarine) and GW0742 in the Athlete's A and B samples collected in:
- Sofia, 26 September 2022;
- Tokyo, 6 October 2022;
- Seoul, 12 October 2022; and
- Poland, 9 November 2022.
Following notification the Athlete admitted the violation, waived his right for a hearing, accepted a provisional suspension and the sanction proposed by the ITIA.
The Athlete denied that the violation was intentional and assumed that one of the prescribed supplement he had used could be the source of these banned substances. He asserted with evidence that he properly had researched the ingredients of his supplements before using.
Thereupon analysis of the supplement INTRA in a Laboratory revealed the presence of prohibited contaminants. Furthermore the Montreal Laboratory confirmed that the test results were consistent with the Athlete's use of this supplement at the material time.
In view of the evidence the ITIA accepts that the Athlete has demonstrated that the violation was not intentional as a result of his use of a contaminated supplement. Considering the Athlete's conduct in this case the ITIA determines that he acted with No Significant Fault or Negligence.
Therefore the ITIA decides on 16 June 2023 to impose a 13 month period of ineligibility on the Athlete, starting on the date of the provisional suspension, i.e. on 30 November 2022.
